MRI, CT, PET‑CT and other imaging delivered across Europe, the Middle East and global markets.

We offer large‑scale scanning capacity, clinical excellence and operational efficiency to support international health systems alongside public and private partners and patients.

PET-CT sits at the heart of modern molecular imaging, helping clinicians understand how disease is behaving, not just where it is located.

Supported by specialist radiopharmaceutical expertise, molecular imaging plays an increasingly important role in personalised care.

Effective screening programmes depend on access, participation and delivery at scale.

Working with healthcare providers across multiple regions, we help expand screening services that support earlier detection and long-term population health.

Cyclotrons, radiotracers and reliable radiopharmaceutical supply chains supporting PET‑CT and therapeutic pathways.

With 12 manufacturing sites and specialist operational teams, we ensure reliability and proximity to point of care, enabling safe, timely diagnosis at scale.

Radiotherapy services supporting cancer pathways through advanced treatment planning, clinical expertise and integrated care delivery.

Across our regions, we help health systems expand access to radiotherapy services, combining operational excellence, specialist teams and a patient-centred approach to cancer treatment.

Clinical studies, technology validation and AI‑ready datasets drawn from our extensive network help accelerate diagnostic innovation.

Our R&D function supports discovery, evidence generation and development of safer, more effective clinical and AI technologies.